Barclays
CMPX icon

Barclays’s Compass Therapeutics CMPX Stock Holding History

Barclays’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Sell
50,397
-739,644
-94% -$2.18M ﹤0.01% 3991
2026
Q1 		$4.18M Buy
790,041
+195,265
+33% +$1.13M ﹤0.01% 1929
2025
Q4 		$3.19M Buy
594,776
+372,358
+167% +$1.72M ﹤0.01% 2590
2025
Q3 		$778K Sell
222,418
-19,303
-8% -$61K ﹤0.01% 3523
2025
Q2 		$628K Buy
241,721
+122,990
+104% +$254K ﹤0.01% 3631
2025
Q1 		$226K Sell
118,731
-74,035
-38% -$197K ﹤0.01% 3979
2024
Q4 		$280K Buy
192,766
+22,521
+13% +$37.4K ﹤0.01% 4147
2024
Q3 		$313K Buy
170,245
+112,614
+195% +$140K ﹤0.01% 4055
2024
Q2 		$57.6K Sell
57,631
-18,282
-24% -$26.7K ﹤0.01% 4151
2024
Q1 		$150K Sell
75,913
-49,573
-40% -$85.7K ﹤0.01% 4259
2023
Q4 		$196K Buy
125,486
+95,183
+314% +$165K ﹤0.01% 4428
2023
Q3 		$59.7K Sell
30,303
-1,618
-5% -$4K ﹤0.01% 3797
2023
Q2 		$102K Sell
31,921
-9,065
-22% -$28.5K ﹤0.01% 3557
2023
Q1 		$134K Buy
40,986
+22,761
+125% +$89.4K ﹤0.01% 4021
2022
Q4 		$91.7K Buy
18,225
+17,851
+4,773% +$71.2K ﹤0.01% 4276
2022
Q3 		$1K Buy
+374
New +$1.03K ﹤0.01% 4680

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's CMPX Position: Q2 2026 in Review

Barclays reduced its Compass Therapeutics (CMPX) stake by 94% in Q2 2026, selling an estimated $2.18M and leaving 50,397 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

Barclays first reported a position in CMPX in Q3 2022 and has held it in 16 quarters since. The position peaked at $4.18M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Barclays held 50,397 shares of Compass Therapeutics worth $110K as of Q2 2026.
  • Barclays sold 739,644 Compass Therapeutics shares in Q2 2026, an estimated $2.18M.
  • Compass Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3991 holding.
  • Barclays first reported a position in Compass Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Barclays's Compass Therapeutics position peaked at $4.18M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.